Skip to main content

Advertisement

SpringerLink
Log in

Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

To investigate the effect of solifenacin succinate on intraocular pressure (IOP) and dry eye in patients with overactive bladder (OAB).

Methods

The study was conducted prospectively between October 2014 and November 2015. A total of 93 female OAB patients with a mean age of 48.59 ± 11.28 years (range 19–75 years) were evaluated. A full ophthalmic examination, including the Schirmer I test and IOP measurements, was conducted. Solifenacin succinate (5 mg/day) was started orally. All procedures were repeated at the 4- and 12-week follow-up, and the effects and side effects were documented.

Results

No statistically significant difference was observed in IOP (p = 0.282, p = 0.189) and tear secretion (p = 0.122, p = 0.071) values from the baseline (day 0) to the 12th week in OAB patients using solifenacin succinate. Solifenacin succinate treatment was terminated in 3 patients owing to dry eye in 1 patient, increased IOP in 1 patient, and systemic side effects in 1 patient. Constipation and dry mouth at various rates were the most common systemic side effects observed.

Conclusions

Solifenacin succinate is useful in eliminating OAB symptoms in female patients, but can cause systemic side effects. It had no significant side effects on tear secretion (Schirmer I) and IOP. We concluded that solifenacin succinate could be reliably used in pure OAB patients without comorbidity in terms of dry eye and IOP. We believe that prospective studies with larger series are still needed to reach a definite conclusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jain D, Dhua A, Ravisankar V, Chellam L, Joshi MJ. Acute angle closure glaucoma after hypospadias surgery: a vision-threatening complication of oxybutynin. J Indian Assoc Pediatr Surg. 2015;20(3):161–2. doi:10.4103/0971-9261.154662.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Homma Y, Kakizaki H, Gotoh M, et al. Epidemiologic survey on urination. J Jpn Neurogenic Bladder Soc. 2003;14:266–77.

    Google Scholar 

  3. Andersson K-E, Yoshida M. Antimuscarinics and the overactive detrusor―which is the main mechanism of action? Eur Urol. 2003;43(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  4. Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005;144:1089–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83:259–69.

    Article  CAS  PubMed  Google Scholar 

  6. Lai HH, Boone T, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol. 2002;4:28–37.

    Google Scholar 

  7. Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol. 2004;44:1023–33.

    Article  CAS  PubMed  Google Scholar 

  8. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46–53.

    Article  CAS  PubMed  Google Scholar 

  9. Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006;28:1935–46.

    Article  CAS  PubMed  Google Scholar 

  10. Sekeroglu MA, Hekimoglu E, Tasci Y, Dolen I, Arslan U. Ocular surface changes following oral anticholinergic use for overactive bladder. Cutan Ocul Toxicol. 2015;4:1–4.

    Google Scholar 

  11. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.

    Article  CAS  PubMed  Google Scholar 

  12. Ouslander JG, Blaustein J, Connor A, Orzeck S, Yong CL. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol. 1988;140(1):47–50.

    CAS  PubMed  Google Scholar 

  13. Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, Guyel S, Ozkardes H. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol. 2005;59(5):588–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U. The effect of oral solifenacin succinate on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J. 2014;25(11):1479–82.

    Article  PubMed  Google Scholar 

  15. Sung VC, Corridan PG. Acute-angle closure glaucoma as a side-effect of oxybutynin. Br J Urol. 1998;81(4):634–5.

    Article  CAS  PubMed  Google Scholar 

  16. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf. 2003;26(11):749–67.

    Article  CAS  PubMed  Google Scholar 

  17. Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol. 2007;14(7):595–7.

    Article  PubMed  Google Scholar 

  18. Bacman S, Perez Leiros C, Sterin-Borda LŞ, et al. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptor in patients with primary Sjögren’s syndrome. Invest Ophthalmol Vis Sci. 1998;39:151–6.

    CAS  PubMed  Google Scholar 

  19. American Academy of Ophthalmology (2005). External disease and cornea. Basic and clinical science course section 8. San Francisco: AAO. p. 53–61.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey

    Ali Riza Turkoglu, Soner Coban, Muhammet Guzelsoy & Murat Demirbas

  2. Department of Ophthalmology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey

    Neslihan Parmak Yener

  3. Department of Family Medicine, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey

    Hakan Demirci

Authors
  1. Ali Riza Turkoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neslihan Parmak Yener
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soner Coban
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muhammet Guzelsoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Murat Demirbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hakan Demirci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Riza Turkoglu.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turkoglu, A.R., Yener, N.P., Coban, S. et al. Changes in intraocular pressure and tear secretion in patients given 5 mg solifenacin for the treatment of overactive bladder. Int Urogynecol J 28, 777–781 (2017). https://doi.org/10.1007/s00192-016-3199-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-016-3199-x

Keywords

Search

Navigation